Writing Your Outcomes Case in the Commissioner's Language, Not Yours

A commissioning panel reads dozens of bids a cycle. Most of them describe a social connection programme in the language of the people who run it: belonging, wellbeing, “a sense of community.” That language is honest and it is also the wrong currency. Commissioners are scoring against a business case, a budget line, and usually a health or care outcome they are accountable for upstream. If your evaluation plan speaks wellbeing and their scoring framework speaks risk reduction and service use, you lose marks before anyone doubts your delivery model.

This note is about the translation, not the delivery. If your programme works, the fix here is entirely about how you write the case.

Start from what the commissioner is already accountable for

Before you draft an outcomes framework, find out what indicator the commissioning body is judged against. A clinical commissioning group or integrated care board is judged on emergency attendance, GP appointment volume, and admission rates. A local authority public health team is judged against indicators reported to national bodies. An employer’s occupational health budget is judged on absence and turnover. None of these bodies is scored on “loneliness reduced.” They are scored on the downstream thing loneliness affects.

That means your job is not to prove your programme reduces loneliness — the panel probably already believes that connection matters. Your job is to state, in one sentence, which line on their scorecard your programme plausibly moves, and to be honest about how strong the “plausibly” is.

The three claims a commissioner will actually credit

There is a hierarchy of claims that land differently with a funding panel, roughly in order of how much scrutiny they survive.

Claim 1: Connection is a comparable risk factor. The evidence base here is genuinely strong, and it is worth quoting precisely rather than loosely. Julianne Holt-Lunstad’s 2010 meta-analysis, covering 148 studies and over 308,000 participants, found stronger social relationships associated with a 50% increased likelihood of survival — an effect size the authors describe as comparable to established risk factors like smoking. Her 2015 follow-up put social isolation at an odds ratio of 1.29 for early mortality, loneliness at 1.26, and living alone at 1.32, with effects holding after adjusting for health status. The 2022 American Heart Association scientific statement adds a specific, commissioner-legible figure: social isolation and loneliness are associated with roughly a 29% increased risk of heart attack or death from heart disease, and a 32% increased risk of stroke. This is the claim to lead with in any bid to a health commissioner, because it converts your programme’s territory into the language of cardiovascular and mortality risk that every health body already tracks.

Claim 2: Connection is a modifiable risk factor, not just a marker. Holt-Lunstad’s 2021 review in the American Journal of Lifestyle Medicine argues explicitly for placing social connection alongside diet, exercise, and smoking cessation in preventive health frameworks. This is a useful sentence for a bid because it puts your programme in the same conceptual bucket as things commissioners already fund — it says “we belong in the prevention budget,” not “we belong in the community grants pot.”

Claim 3: Specific delivery models change specific outcomes. This is where you need to slow down, because it is where most bids overreach. Systematic reviews of social prescribing report consistent positive findings on self-esteem and self-confidence, and some studies within those reviews report reduced GP, emergency, social worker, or inpatient service use. But the reviews themselves flag limited trial evidence and heterogeneous programme designs — the 2021 systematic review on loneliness and social prescribing found all nine included studies reported positive impacts, with only three reporting service-use reductions, and the 2021 wellbeing-focused review is explicit about the weakness of the underlying trial base. Do not present “social prescribing reduces GP visits” as an established causal fact. Present it as a directionally consistent finding across a small evidence base, and say what your own programme’s monitoring will add to it.

Evidence-status table for your outcomes section

Claim	Evidence status
Weak social connection carries mortality risk comparable to smoking or obesity	Strong — large meta-analytic base, replicated across two decades
Social isolation and loneliness raise cardiovascular and stroke risk	Strong — 2022 AHA scientific statement, specific effect sizes
Social connection is a modifiable, preventable risk factor	Reasonably strong as a conceptual argument; weak on which interventions modify it at scale
Social prescribing improves self-esteem and confidence	Moderate — consistent across reviews, small studies, no controls in most
Social prescribing reduces NHS service use	Weak — reported in a minority of included studies, not a general finding
Structured, purposeful activity produces more benefit than casual social contact	Emerging — qualitative synthesis evidence, not yet quantified

That last row draws on a 2022 qualitative meta-synthesis in BMC Health Services Research, which found that people attribute benefit to social prescribing less to social contact itself and more to restored participation and purpose — a useful distinction if your programme is a structured activity rather than a drop-in.

What this means in practice: put the mortality and cardiovascular risk evidence in your opening paragraph, because it is where the panel’s own accountability sits. Put your programme-level service-use claims in a separate, hedged paragraph, and attach them to your own monitoring plan rather than to the wider literature. Do not let the strength of the first claim lend false authority to the second.

The failure mode: the warm-glow close

The most common way a strong bid loses marks in the outcomes section is what can be called the warm-glow close — a final paragraph that shifts from risk-factor language back into wellbeing language, undoing the translation you did earlier. “This programme will reduce isolation and help people feel more connected to their community” is a sentence a commissioner has read fifty times. It does not tell them which line item moves. Every outcomes paragraph should end on a measurable proxy for something the commissioning body is already accountable for — attendance figures, a validated loneliness scale score change, self-reported GP contact, absence days — not on a description of how participants will feel.

The UK’s 2018 national loneliness strategy is a useful reference point here, not because it settles the causal question but because it shows what an official body treats as legitimate measurement: it embedded loneliness tracking into national statistics and funded social prescribing on that basis, treating loneliness as a measurable population indicator rather than a sentiment. If your bid can point to an indicator with that kind of official standing — a validated scale, a recognised health economy metric — do so explicitly, and name it, rather than describing the feeling it is meant to capture.

The National Academies’ 2020 consensus report on older adults is worth citing for a different reason: it calls on health systems to routinely assess isolation and loneliness, which gives you grounds to argue that measurement itself, not just delivery, is something the commissioner should be funding. If your bid includes a screening or assessment component, this report is the citation that justifies it as clinically credible rather than as an add-on.

What this does not solve

None of this makes a weak programme strong. Translating your outcomes into risk-factor language will get a mediocre bid past the first scoring gate and no further — panels that ask for evidence at interview will find the gap between your claims and your data quickly. It also does nothing for the structural problem in the underlying evidence: social prescribing trials remain small, short, and rarely controlled, so no amount of careful framing turns a promising signal into a proven mechanism. And translation works only for commissioners whose scorecards already include a health or service-use metric your programme plausibly touches — for community or arts-funding panels scoring against different criteria entirely, this framework will not fit, and forcing it on will read as evasive rather than rigorous.